(VIANEWS) - Catalent (CTLT), NXP Semiconductors (NXPI), Crane Company (CR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Catalent (CTLT)
21.8% sales growth and 16.22% return on equity
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide.
Catalent's sales growth this year is anticipated to be 27.5% and 9.9% for next year.
Year-on-year quarterly revenue growth grew by 38.5%, now sitting on 3.76B for the twelve trailing months.
Volume
Today's last reported volume for Catalent is 576203 which is 37.93% below its average volume of 928277.
Catalent's sales growth for the next quarter is 21.8%. The company's growth estimates for the ongoing quarter and the next is 14.4% and 51.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.22%.
Volatility
Catalent's last day, last week, and last month's current volatility was 1.97%, 0.85%, and 0.97%, respectively.
Catalent's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.88% (day), 1.76% (last week), and 1.72% (last month), respectively.
Catalent's Stock Yearly Top and Bottom Value
Catalent's stock is valued at $109.70 at 23:22 EST, way under its 52-week high of $127.68 and way higher than its 52-week low of $76.28.
Catalent's Moving Average
Catalent's worth is higher than its 50-day moving average of $107.84 and above its 200-day moving average of $109.32.Previous days news about Catalent(CTLT)
According to MarketWatch on Wednesday, 14 July, "The Russell is off to a weak start for the quarter, which lines up with a , LCI Industries , TopBuild , Ollie's Bargain Outlet , Standard Motor , Casey's General , Nu Skin Enterprises , Vital Farms , Virtu Financial , Integra Life Sciences , Catalent , Pacira Biosciences , Amedisys , SiteOne Landscape , Timken , Builders FirstSource , Ciena and Huntsman ."
According to Bloomberg Quint on Wednesday, 14 July, "The final product is frozen in sterile bioprocessing bags, encased in a protective shell, and shipped in temperature-controlled trucks to Catalent Inc.'s plant in Bloomington, Ind. ", "Moderna also made pacts this year with Sanofi, Samsung Biologics, and Thermo Fisher Scientific to bolster the vial-filling capacity that Catalent and Laboratorios Farmacéuticos Rovi in Spain currently provide. "
2. NXP Semiconductors (NXPI)
20% sales growth and 5.14% return on equity
NXP Semiconductors N.V. offers various semiconductor products.
NXP Semiconductors's sales growth this year is anticipated to be 22.6% and 6.2% for next year.
Year-on-year quarterly revenue growth grew by 27%, now sitting on 9.16B for the twelve trailing months.
Volume
Today's last reported volume for NXP Semiconductors is 3683360 which is 38.54% above its average volume of 2658720.
NXP Semiconductors's sales growth is a negative 0% for the ongoing quarter and 20% for the next. The company's growth estimates for the current quarter and the next is 145.7% and 52.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.14%.
Volatility
NXP Semiconductors's last day, last week, and last month's current volatility was 0.22%, 1.17%, and 1.20%, respectively.
NXP Semiconductors's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.06% (day), 2.40% (last week), and 2.22% (last month), respectively.
NXP Semiconductors's Stock Yearly Top and Bottom Value
NXP Semiconductors's stock is valued at $194.41 at 23:22 EST, way below its 52-week high of $216.43 and way higher than its 52-week low of $114.38.
NXP Semiconductors's Moving Average
NXP Semiconductors's value is below its 50-day moving average of $202.33 and above its 200-day moving average of $191.31.Previous days news about NXP Semiconductors(NXPI)
According to FXStreet on Thursday, 15 July, "Against this backdrop, shares of Nvidia and NXP Semiconductors drop over 4.0% to drag Nasdaq down by 0.70% or 101.80 points to 14,543.10. "
3. Crane Company (CR)
14.3% sales growth and 15.09% return on equity
Crane Co. manufactures and sells engineered industrial products in the United States, Canada, the United Kingdom, Continental Europe, and internationally.
Crane Company's sales growth this year is anticipated to be 5.2% and 5.3% for next year.
Year-on-year quarterly revenue growth grew by 4.5%, now sitting on 2.97B for the twelve trailing months.
Volume
Today's last reported volume for Crane Company is 225640 which is 18.67% below its average volume of 277453.
Crane Company's sales growth for the next quarter is 14.3%. The company's growth estimates for the ongoing quarter and the next is 115.6% and 36.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.09%.
Volatility
Crane Company's last day, last week, and last month's current volatility was 0.86%, 0.91%, and 1.49%, respectively.
Crane Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.36% (day), 1.99% (last week), and 2.30% (last month), respectively.
Crane Company's Stock Yearly Top and Bottom Value
Crane Company's stock is valued at $93.05 at 23:22 EST, below its 52-week high of $99.93 and way higher than its 52-week low of $48.19.
Crane Company's Moving Average
Crane Company's value is above its 50-day moving average of $92.43 and higher than its 200-day moving average of $89.56.4. Meridian Bioscience (VIVO)
10.1% sales growth and 33.88% return on equity
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.
Meridian Bioscience's sales growth this year is anticipated to be 28.5% and a negative 5.2% for next year.
Year-on-year quarterly revenue growth grew by 48.8%, now sitting on 327.13M for the twelve trailing months.
Volume
Today's last reported volume for Meridian Bioscience is 161067 which is 70.65% below its average volume of 548822.
Meridian Bioscience's sales growth is a negative 0% for the current quarter and 10.1% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 43.6% and 150%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.88%.
Volatility
Meridian Bioscience's last day, last week, and last month's current volatility was 0.97%, 1.16%, and 2.38%, respectively.
Meridian Bioscience's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.65% (day), 3.65% (last week), and 4.32% (last month), respectively.
Meridian Bioscience's Stock Yearly Top and Bottom Value
Meridian Bioscience's stock is valued at $22.05 at 23:22 EST, way below its 52-week high of $30.65 and way above its 52-week low of $12.98.